Results 121 to 130 of about 179,181 (243)

PD-L1 in ICI Myocarditis: When the Immune Brake Fails. [PDF]

JACC CardioOncol
Chen AC, Moslehi JJ.
europepmc   +1 more source

Designer Dynamic DNA Nanoaggregate in Living Cell for Mitochondrial Energy Restriction

Advanced Science, EarlyView.
This study presents the Tech‐tetrahedron, a designer dynamic DNA nanoaggregate engineered for precise mitochondrial energy restriction. Its trinity‐functionalized design integrates navigable unit, telomerase‐activated latch, and self‐assembly module.
Ruijia Deng, Jing Sheng, Ben Niu, Wenjuan Fu, Yingjie Yang, Zuowei Xie, Shuang Xie, Yunxuan He, Meilin Gong, Jue Wang, Yan Pi, Ming Chen, Kai Chang   +12 more
wiley   +1 more source

A bibliometric analysis of resistance to PD-1/PD-L1 inhibitors. [PDF]

Front Immunol
Miao L, Jiang Z.
europepmc   +1 more source

Placental Site Trophoblastic Tumor Acquires Immune Functions by Incorporating Host Maternal Genes

Advanced Science, EarlyView.
PSTT cells, through cell fusion with B cells, incorporate abundant non‐inherited maternal genes that are detectable by DNIMA. These hybrid cells acquire immunotherapy‐resistant genetic changes and increase the expression of B cell‐derived immune‐related molecules such as Ig, HLA, LILRB, SIGLEC10, and so on, creating an immunotolerant environment around
Kyosuke Kagami, Masanori Ono, Yasunari Mizumoto, Tatsuhito Kanda, Takashi Iizuka, Takiko Daikoku, Shin‐ichi Horike, Akira Hattori, Akihito Horie, Sachiko Minamiguchi, Tomoko Fujiwara, Kazuyoshi Hosomichi, Atsushi Tajima, Hirokazu Usui, Kaoru Abiko, Hiroshi Fujiwara   +15 more
wiley   +1 more source

Enhancing Non-small Cell Lung Cancer Susceptibility to Anti-PD-1/PD-L1 Therapy through PD-L1 Ligand-Ir(III) Complex Conjugates. [PDF]

Cancer Commun (Lond)
Pagliara V, Assoni G, Polcaro G, Bossi A, Penconi M, Liguori L, Seneci P, Di Leva FS, D'Amore VM, Brancaccio D, Santoro F, Ferrone CR, Ciaglia E, Puca AA, Pepe S, Marinelli L, Arosio D, Sabbatino F.   +17 more
europepmc   +1 more source

Endobody: Genetically Encodable Nanobody‐CPP Chimeras for Degradation of Membrane and Extracellular Proteins

Advanced Science, EarlyView.
We introduced genetically encodable, receptor‐independent nanobody‐CPP chimeras, termed endobodies, as robust and modular membrane protein degraders. Additionally, proteasome‐targeting domain (PTD)‐tethered endobody demonstrates further enhanced degradation potency.
Chengjian Zhou, Huiping He, Simin Xia, Xi Chen   +3 more
wiley   +1 more source

Single‐Cell Reveal GALNT7‐Dependent Ferroptosis Suppression as a Mechanism of Immunotherapy Resistance in Non‐Small Cell Lung Cancer

Advanced Science, EarlyView.
Integrated clinical and mechanistic analyses identify GALNT7 as a ferroptosis‐suppressive regulator associated with immunotherapy resistance in non‐small cell lung cancer. GALNT7 depletion promotes lipid peroxidation, mitochondrial dysfunction, and ferroptosis, enhances CD8+ T‐cell activation and IFN‐γ production, and sensitizes tumors to PD‐1 blockade,
Jiadi Gan, Qian Zheng, Deng Liu, Ruichao Nie, Menglin Yao, Xiaolong Tang, Renjie Xu, Jinghong Xian, Wenjun Meng, Wenxin Luo, Dan Liu, Guiyi Ji   +11 more
wiley   +1 more source

Nuclear PD-L1: an emerging oncogenic driver and promising therapeutic target in cancer. [PDF]

J Biomed Sci
Guo C, Fan Z, Guo C, Yang Y, Hou H, Sun D.   +5 more
europepmc   +1 more source

Membrane Fusion‐Mediated Cytosolic Delivery of Threose Nucleic Acids via Homotypic Nanoparticles Overcomes Drug Resistance in Triple‐Negative Breast Cancer

Advanced Science, EarlyView.
This study introduces a biomimetic “nanofusion” platform that integrates the biostability of threose nucleic acids (TNA) with homotypic cell‐membrane cloaking to combat drug‐resistant TNBC. By leveraging a non‐canonical membrane‐fusion pathway for direct cytosolic delivery, the platform bypasses endosomal sequestration. To achieve potent AKT2 silencing
Wei Zheng, Tristan Juin Han Chang, Xinchao Li, Zhongqi Zhou, Chung Tin, Kenward Vong, Pierre Karam, Pik Kwan Lo   +7 more
wiley   +1 more source

Overcoming resistance to anti-PD-1/PD-L1 therapy in cancer. [PDF]

Cancer Drug Resist
Li L, Zhao Y, Shi X, Guo X, Zhang X, Li G, Meng Q, Zhang M, Yin M.   +8 more
europepmc   +1 more source